dm+d

Unassigned

New Medicines

LonsurfUnresectable or metastatic colorectal cancer - first-line in combination with bevacizumab in patients not suitable for standard full dose combination chemotherapy with irinotecan or oxaliplatin

Information

Lonsurf
Licence extension / variation
Servier
Taiho

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Oct 21Development discontinued as the primary objective (progression free survival) of the PIII SOLSTICE trial to evaluate the superiority of trifluridine/tipiracil + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy has not been met [4].

Category

Lonsurf is comprised of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride, at a molar ratio 1:0.5
Colorectal cancer is the fourth most common cancer in the UK after breast, prostate and lung cancer. There were 42,300 new cases of bowel cancer registered each year in the UK in 2015-2017 [1].
Unresectable or metastatic colorectal cancer - first-line in combination with bevacizumab in patients not suitable for standard full dose combination chemotherapy with irinotecan or oxaliplatin
Oral